|Bid||5.06 x 1300|
|Ask||5.07 x 800|
|Day's Range||5.02 - 5.13|
|52 Week Range||2.23 - 7.21|
|Beta (3Y Monthly)||1.67|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 6, 2019 - May 10, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.29|
ArQule, Inc. (ARQL) today announced that Robert Weiskopf, Senior Vice President, Chief Financial Officer and Treasurer, has decided to retire effective March 29 of this year. In conjunction with Mr. Weiskopf’s departure, ArQule is naming Marc Schegerin, MD as Chief Financial Officer and Head of Strategy, effective as of Mr. Weiskopf’s retirement. Dr. Schegerin joined ArQule in May 2018 and most recently served as Senior Vice President, Head of Strategy, Finance and Communication.
ArQule, Inc. (ARQL) today announced that Peter Lawrence, President and Chief Operating Officer, and Brian Schwartz, MD, Chief Medical Officer and Head of Research and Development, of ArQule will present at Oppenheimer’s 29th Annual Healthcare Conference on March 20, 2019 at 10:20 a.m. ET at the Westin New York Grand Central in New York City. The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, www.arqule.com, under “Events & Presentations.” A replay of the webcast will be available shortly after the conclusion of the presentation.
ArQule, Inc. today announced that Paolo Pucci, Chief Executive Officer, and Marc Schegerin, Senior Vice President and Head of Strategy, Finance and Communication, will participate in the 31st Annual ROTH Conference on March 17-19, 2019 in Dana Point, California.
Paolo Pucci has been the CEO of ArQule, Inc. (NASDAQ:ARQL) since 2008. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similarRead More...
NEW YORK, Feb. 26, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
ArQule, Inc. (ARQL), today announced the publication of clinical pharmacodynamic, safety and efficacy data in patients with Proteus syndrome. The study, published in the American Journal of Human Genetics, and led by the National Institutes of Health (NIH), demonstrated good target engagement, tolerability and reductions in lesion size and pain, especially in children.
ArQule, Inc. (ARQL) today announced it will report financial results for the fourth quarter and full year of 2018 before the market opens on Thursday, March 7, 2019. The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and provide a general business update. ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases.
ArQule, Inc. (ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Brian Schwartz, M.D., Chief Medical Officer and Head of Research and Development, of ArQule will present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019, at 11:30 a.m. ET at the Lotte New York Palace in New York City. The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, www.arqule.com, under “Events & Presentations.” A replay of the webcast will be available shortly after the conclusion of the presentation.
ArQule, Inc.’s (ARQL) partner, Basilea Pharmaceutica Ltd. (SIX:BSLN), announced today that it entered into a collaboration with Roche (SIX: RO, ROG) to explore a combination of derazantinib (BAL087) and Roche’s PD-L1-blocking immune-checkpoint inhibitor, atezolizumab (Tecentriq®), in patients with urothelial cancer. Basilea expects to start a biomarker-driven multi-cohort phase 1/2 study in mid-2019. The planned study will assess the safety, tolerability and efficacy of the derazantinib-atezolizumab combination in patients with advanced urothelial cancer and confirmed FGFR genomic aberrations.
The analysis showed promising activity in patients with FGFR2 gene fusion-expressing intrahepatic cholangiocarcinoma (iCCA) and also confirmed the safety profile and tolerability of the drug candidate observed in previous clinical studies.
If you're interested in ArQule, Inc. (NASDAQ:ARQL), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact Read More...
Premier Health Group (PHGRF) (PHGI), ArQule, Inc (ARQL), Amarin Corporation plc (AMRN), and AVEO Pharmaceuticals, Inc (AVEO) are 4 pharma stocks that may be worth keeping tabs on this week. Premier Health Group (PHGRF) (PHGI) is a company determined to improve the quality of care currently made available to consumers in the primary healthcare space. As an industry leader, the Company is focused on developing proprietary technologies to develop healthcare through a network of interconnected primary care clinics by way of artificial intelligence integration and telemedical advancements.
HENDERSON, NV / ACCESSWIRE / December 26, 2018 / The news isn't all gloom and doom, the biotech companies highlighted below have all released positive news recently. We are highlighting: Endonovo Therapeutics, ...
NEW YORK, Dec. 26, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
ArQule, Inc. (ARQL) today announced that it has been selected for inclusion in the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 24, 2018. The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB) and that meet certain eligibility criteria. The NBI is re-ranked annually and forms the basis for a number of Exchange Traded Funds (ETFs), including the iShares Nasdaq Biotechnology ETF.
Before we spend days researching a stock idea we’d like to take a look at how hedge funds and billionaire investors recently traded that stock. S&P 500 Index ETF (SPY) lost 8.7% through October 26th. Forty percent of the S&P 500 constituents were down more than 10%. The average return of a randomly picked stock […]
ArQule, Inc. (ARQL) yesterday presented preliminary results from the Company’s Phase 1 dose escalation study for ARQ 531, an orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK) in patients with relapsed or refractory hematologic malignancies at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego.
Large-cap pharma stocks are seeing some upward momentum and are on track to finish the year with handsome gains. As the year draws to a close, it remains to be seen if these stocks can sustain the ongoing ...